Albert Labs International (XCNQ:ABRT) EPS (Basic) : C$-0.05 (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International EPS (Basic)?

Albert Labs International's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was C$0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was C$-0.05.

Albert Labs International's EPS (Diluted) for the three months ended in Sep. 2023 was C$0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was C$-0.05.

Albert Labs International's EPS without NRI for the three months ended in Sep. 2023 was C$0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Albert Labs International EPS (Basic) Historical Data

The historical data trend for Albert Labs International's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International EPS (Basic) Chart

Albert Labs International Annual Data

Trend

Dec21

Dec22

EPS (Basic)

-0.03

-0.13

Albert Labs International Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Basic)	Get a 7-Day Free Trial					-0.01	-0.04	-0.01	-	-

Albert Labs International EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Albert Labs International's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.059	-	0)	/	56.415
	=	-0.13

Albert Labs International's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.017	-	0)	/	74.413
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05

Albert Labs International (XCNQ:ABRT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Albert Labs International EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Albert Labs International's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Albert Labs International (XCNQ:ABRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6

Website

https://www.albertlabs.com

Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines